Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female of non-childbearing potential or male~* Age above or equal to 18 years at the time of signing informed consent~* Body mass index (BMI) greater than or equal to 27.0 kg/m\^2~* Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening~* Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening~* Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at maximum tolerated or effective dose as judged by the investigator: metformin with or without Sodium-glucose co-transporter-2 (SGLT2) inhibitor~Exclusion Criteria:~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days and prior insulin treatment for gestational diabetes are allowed~* Renal impairment with estimated Glomerular Filtration Rate (eGFR) below 60 ml/min/1.73m\^2 by central laboratory at screening~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cagrilintide 2.4 mg and semaglutide 2.4 mg (Type: EXPERIMENTAL): Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
- Cagrilintide 2.4 mg and placebo (semaglutide) (Type: ACTIVE_COMPARATOR): Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
- Semaglutide 2.4 mg and Placebo (cagrilintide) (Type: ACTIVE_COMPARATOR): Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).